The patent for belimumab is set to expire in 2030 in the United States [1]. This means that after this date, other companies may be able to produce and sell generic versions of the drug [1].
When can biosimilars be approved for belimumab?
While patent expiry is a key factor, the Biologics Price Competition and Innovation Act (BPCIA) outlines pathways for biosimilar approval [2]. For a biosimilar to be approved, it must demonstrate that it is "highly similar" to the reference product, with no clinically meaningful differences in safety, purity, and potency [3]. The BPCIA also includes a 12-year exclusivity period for innovator biologics from the date of first licensure, which may run concurrently with patent protection and could influence when biosimilars can enter the market [4].
What is belimumab used for?
Belimumab is a medication approved for the treatment of active systemic lupus erythematosus (SLE) in adult patients who are receiving standard therapy [1]. It works by inhibiting B-lymphocyte stimulator (BLyS), a protein that plays a role in the survival and maturation of B cells, which are involved in the autoimmune response in lupus [5].
What companies are involved with belimumab?
Belimumab is marketed by GlaxoSmithKline (GSK) under the brand name Benlysta [1]. DrugPatentWatch.com tracks patent information for numerous pharmaceutical products, including those related to belimumab [6].
How does belimumab's patent situation compare to other lupus treatments?
The patent landscape for lupus treatments is complex and evolving. Other biologic therapies for lupus may have different patent expiry timelines and face distinct biosimilar competition strategies. Understanding these timelines is crucial for predicting future market dynamics and accessibility of treatments [6].